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Background: Total intravenous anesthesia (TIVA) is used widely in spinal surgery because inhalational anesthetics
are known to decrease the amplitude of motor evoked potentials. Presently, dexmedetomidine is used as an
adjuvant for propofol-based TIVA. We compared the effects of remifentanil and dexmedetomidine on pain intensity
as well as the analgesic requirements after post-anesthesia care unit (PACU) discharge in patients undergoing spinal
surgery.
Methods: Forty patients scheduled for posterior lumbar interbody fusion (PLIF) surgery under general anesthesia
were enrolled. Anesthesia was maintained using propofol at 3–12 mg/kg/h and remifentanil at 0.01–0.2 μg/kg/min
in Remifentanil group or dexmedetomidine at 0.01–0.02 μg/kg/min in Dexmedetomidine group, keeping the
bispectral index between 40 and 60. Patient-controlled analgesia (PCA) made of hydromophone was applied once
the patients opened their eyes in the PACU. The visual analog scale (VAS) score, PCA dosage administered, and
postoperative nausea and vomiting (PONV) were recorded at the time of discharge from the PACU (T1) and at
2 (T2), 8 (T3), 24 (T4), and 48 hours (T5) after surgery.
Results: The VAS score in Remifentanil group was significantly higher than that in Dexmedetomidine group at
immediate and late postoperative period (4.1 ± 2.0 vs. 2.3 ± 2.2 at T1, and 4.0 ± 2.2 vs. 2.6 ± 1.7 at T5; P < 0.05).
Dexmedtomidine group had a statistically significantly lower PCA requirement at every time point after surgery
except directly before discharge from the PACU (3.0 ± 1.2 ml vs. 2.3 ± 1.4 ml at T1; P > 0.05, but 69.7 ± 21.4 ml vs.
52.8 ± 10.8 ml at T5; P < 0.05). Patients in Remifentanil group displayed more PONV until 24 hours post-surgery.
Conclusions: Dexmedetomidine displayed superior efficacy in alleviating pain and in postoperative pain
management for 48 hours after PLIF. Therefore, dexmedetomidine may be used instead of remifentanil as an
adjuvant in propofol-based TIVA.
Trial registration: Clinical Research Information Service (CRiS) Identifier: KCT0001041.
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Total intravenous anesthesia (TIVA) is widely used in
spinal surgery because inhalational anesthetics are
known to decrease the amplitude of motor evoked po-
tentials, an important method of intraoperative moni-
toring [1,2]. Remifentanil is a standard adjuvant for
propofol-based TIVA, having a rapid onset and ultra-* Correspondence: jiyo1004@catholic.ac.kr
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unless otherwise stated.short duration of action. Although remifentanil provides
rapid recovery from anesthesia, long-term infusion may
cause opioid-induced hyperalgesia (OIH) [3,4].
α2-adrenoreceptor agonist have been used as the sole
analgesic agents during and after surgery [5]. Dexmedeto-
midine is a selective α2-adrenoreceptor agonist possessing
properties of sedation, anxiolysis, and analgesia without
the development of respiratory depression [6,7]. Its
shorter duration of action (plasma half-life ~2.3 hours)
comparing to clonidine and anesthetic-sparing effect have
led to dexmedetomidine usage as an adjuvant in general. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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now used increasingly as an adjuvant for propofol-based
TIVA [10,11].
Several studies have shown that dexmedetomidine has
superior efficacy compared to remifentanil and other
opioids in immediate postoperative pain management in
the post-anesthesia care unit (PACU) [8,12,13]. However,
no studies have reported whether dexmedetomidine or
remifentanil as an adjuvant in propofol-based TIVA re-
sults in differences in long-term postoperative pain and
recovery quality after discharge from the PACU. There-
fore, we compared the effects of remifentanil and dex-
medetomidine on pain intensity, analgesic requirements,
and postoperative nausea and vomiting (PONV) after
discharge from the PACU in patients undergoing spinal
surgery.
Methods
This study was approved by the Ethical Committee of
Seoul St. Mary’s Hospital, Catholic University of Korea,
and was registered at Clinical Research Information
Service (CRiS, http://cris.nih.go.kr, ID: KCT0001041).
We obtained written informed consent from the partici-
pants. Forty patients (aged 18–70 years, American Soci-
ety of Anesthesiologists physical status I or II) who were
suffering from lumbar herniated nucleus pulposus,
spinal stenosis, spondylolysis and spondylolisthesis, and
scheduled for posterior lumbar interbody fusion (PLIF)
surgery under general anesthesia were enrolled from
September 2013 to January 2014. Patients with coro-
nary artery or ischemic disease, who had bradycardia
(<50 bpm) or an arrhythmia, or who were allergic to the
study drugs were excluded. The patients were allocated
to Remifentanil group or Dexmedetomidine group, re-
ceiving remifentanil or dexmedetomidine, respectively,
as a TIVA adjuvant using computerized single block
randomization. The drugs were prepared in a 50-ml
syringe mixed with normal saline.
The patients were not premedicated, and a 20-gauge
venous cannula was inserted to administer Ringer’s lac-
tated solution. On arrival in the operating room, nonin-
vasive blood pressure monitoring, electrocardiography
using lead II, pulse oximetry, and capnography were
applied and performed continuously. Bispectral index
(BIS) electrodes were placed on the forehead to monitor
the degree of anesthesia. Prior to anesthesia induction in
Remifentanil group, 0.01 μg/ kg/min of remifentanil
(i.e., 0.5 μg/min for 50 kg patient) was adminis-
tered continuously using target-controlled infusion (TCI)
(Orchestra® Workstation; Fresenius Kabi, Bad Homburg,
Germany), whereas 0.01 μg/kg/min of dexmedetomidine
(i.e., 0.5 μg/min for 50 kg patient) was administered
continuously using a syringe pump (Terufusion® Syringe
Pump; Terumo Corp., Tokyo, Japan) in Dexmedetomidinegroup. After 10 minutes of study drug infusion, 1–2 mg/kg
of propofol was manually administered in increments of
20 mg every 15 seconds until BIS reached 40–50. When
the patients were fully sedated (BIS 40–50), 1 mg/kg of
rocuronium was administered and the trachea was intu-
bated after manual ventilation for 1 minute. Anesthesia
was maintained using propofol at 3–12 mg/kg/h (i.e.,
150–600 mg/hr for 50 kg patient) using TCI (Orchestra®
Workstation; Fresenius Kabi) with remifentanil at 0.01-
0.2 μg/kg/min (i.e., 0.5-10 μg/min for 50 kg patient) in
Remifentnai group or dexmedetomidine at 0.01–0.02 μg/
kg/min (e.g. 0.5-1.0 μg/min for 50 kg patient) in Dexme-
detomidine group, keeping the BIS between 40 and 60
and hemodynamic changes < 20% of baseline in both
groups. Mechanical ventilation was maintained using air
(50%) and oxygen (50%), with an end-tidal CO2 of 30–
40 mmHg in both groups. Remifentanil was discontinued
on completion of skin closure in Remifentanil group,
whereas dexmedetomidine was ceased when skin closure
was started in Dexmedetomidine group, taking into
consideration their respective half-times [14,15]. Propofol
was terminated upon the completion of skin closure.
On completion of surgery, 0.3 mg of ramosetron was
administered for PONV, while 0.2 mg/kg of pyridostig-
mine and 0.008 mg/kg of glycopyrrolate were admi-
nistered to reverse muscle relaxation. The trachea was
extubated once spontaneous ventilation of the patient
was adequate and the patients were transferred to the
PACU. Patient-controlled analgesia (PCA) was applied
when the patients opened their eyes in the PACU. PCA
consisted of 12 mg of hydromorphone in 100 ml of nor-
mal saline and was administered using an AutoMed
3200 pump (AutoMed 3000 Series® Ambulatory Infusion
Pump; ACE Medical Corp. Ltd., Seoul, Korea) at a back-
ground rate of 1 ml/h and a bolus dose of 1 ml with a
lockout interval of 10 minutes. In the PACU and gene-
ral ward, 1 μg/kg of fentanyl and 50 mg of tramadol
were intravenously administered, respectively, as rescue
analgesics.
The visual analog scale (VAS) score, amount of PCA
administered, rescue analgesics required, and PONV
were recorded at the time of discharge from the PACU
(T1) and at 2 (T2), 8 (T3), 24 (T4), and 48 hours (T5)
after surgery by a designated nurse who was blinded to
the group allocation. The nurse was educated on the
VAS and PONV by the anesthesiologists. The surgery
and anesthesia duration, the first time of eye opening,
verbal command response, rescue analgesics requests,
and PACU stay duration were also recorded. Patients
were discharged from the PACU after achieving a post-
anesthesia recovery score (modified Aldrete scale) ≥ 8.
The necessary sample size was calculated based on a
pilot study. Seventeen patients in each group were
required to detect a difference of “1 over 10” in the VAS
Figure 1 Consort flow diagram.
Table 1 Demographic data
Remifentanil group Dexmedetomidine group
Sex (M/F) 8/10 8/11
Age (y) 65.1 ± 5.3 65.9 ± 5.8
Weight (kg) 62.5 ± 6.9 63.1 ± 4.3
Height (cm) 158.0 ± 6.5 159.1 ± 2.1
Hypertension 9 (50) 10 (52.6)
Diabetes mellitus 7 (38.9) 7 (36.8)
Preoperative VAS 3.1 ± 0.7 3.1 ± 1.1
VAS, visual analog scale.
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compensate for dropouts and deviations from normality,
40 patients were enrolled. We targeted an 80% proba-
bility (β = 0.2) with a significance level (α) of 0.05 and a
10% dropout; thus, 20 patients were required in each
group. A statistical analysis was performed using SPSS
software (ver. 18.0; SPSS, Inc., Chicago, IL, USA). After
assessing normality, continuous data were compared
using Student’s t-test, while the Mann–Whitney test
was performed to compare non-continuous and non-
normally distributed data. Chi-squared or Fisher’s exact
tests were performed to compare categorical data be-
tween the two groups. All data are presented as the
mean ± standard deviation. A value of P < 0.05 was con-
sidered to indicate statistical significance.
Results
Forty patients were enrolled, of whom two were
excluded from Remifentnail group through follow-up
loss and one from Dexmedetomidine group because of
massive intraoperative bleeding (Figure 1). In total, 37
patients were included in the data analyses and there
was no significant difference in demographic characteris-
tics between the two groups (Table 1). The total amount
of propofol used was not significantly different. Incontrast, the time of eye opening and first verbal com-
mand response in the PACU were significantly delayed
in Dexmedetomidine group compared to Remifentanil
group (P < 0.05). In addition, significantly more patients
in Remifentanil group required rescue analgesics during
the early recovery period in the PACU (P < 0.05). How-
ever, the PACU stay duration was not significantly diffe-
rent between the two groups (Table 2).
The VAS score in Remifentanil group was significantly
higher than in Dexmedetomidine group at every time
point after surgery (4.1 ± 2.0 vs. 2.3 ± 2.2 at T1, and
4.0 ± 2.2 vs. 2.6 ± 1.7 at T5; P < 0.05; Figure 2). Dexmed-
tomidine group had a statistically significantly lower
Table 2 Intraoperative and recovery data
Remifetnanil group Dexmedetomidine group P-value
Duration of surgery (min) 171.1 ± 23.2 177.2 ± 23.9 0.376
Duration of anesthesia (min) 212.3 ± 26.3 214.3 ± 21.6 0.314
Propofol used (mg/kg/h) 7.2 ± 1.2 7.8 ± 1.2 0.632
Remifentanil used (μg/kg/min) 0.10 ± 0.03
Dexmedetomidine used (μg/kg/min) 0.01 ± 0.01
Time of eye opening (min) 6.9 ± 5.5 21.3 ± 4.9 0.001
Time of first verbal command response (min) 12.8 ± 9.3 23.2 ± 6.8 0.027
Incidence of rescue analgesics requirement, n (%) 16 (88.9) 12 (63.2) 0.018
Time of rescue analgesics requirement (min) 13.0 ± 10.2 29.9 ± 11.6 0.011
Incidence of PONV, n (%) 5 (27.8) 0 (0) 0.003
Duration of PACU stay (min) 79.2 ± 18.5 76.6 ± 13.5 0.785
Data are presented as mean ± SD or number (proportion).
PONV, postoperative nausea and vomiting; PACU, postanesthesia care unit.
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directly before discharge from the PACU (3.0 ± 1.2 ml
vs. 2.3 ± 1.4 ml at T1; P > 0.05, and 69.7 ± 21.4 ml vs.
52.8 ± 10.8 ml at T5; P < 0.05; 1 ml = 0.12 mg hydromo-
phone; Figure 3). Finally, the patients in Remifentanil
group required more rescue analgesics at every time point
after surgery and displayed more PONV until 24 hours
post-surgery (P < 0.05; Table 3).Figure 2 Comparison of postoperative VAS scores between the group
after surgery; T3 = 8 hours after surgery; T4 = 24 hours after surgery; T5 = 48Discussion
This is the first report in which dexmedetomidine as an
adjuvant in propofol-based TIVA has been suggested to
alleviate postoperative pain beyond the immediate post-
operative period in the PACU. This study demonstrates
that dexmedetomidine had superior pain control efficacy
compared to remifentanil for the first 48 hours following
PLIF surgery, lowering the VAS score and reducing thes. VAS = visual analog scale; T1 = before PACU discharge; T2 = 2 hours
hours after surgery. *P < 0.05.
Figure 3 Comparison of postoperative PCA use between the groups. PCA = patient-controlled analgesia; T1 = before PACU discharge;
T2 = 2 hours after surgery; T3 = 8 hours after surgery; T4 = 24 hours after surgery; T5 = 48 hours after surgery. *P < 0.05.
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analgesic requirement and PONV incidence compared
to remifentanil. Late postoperative pain may progress to
pathological pain, whereas immediate postoperative pain
is mainly acute physiological pain; pathologic pain differs
from physiologic pain in that it is excessive in intensity
and spread and can be activated by low-intensity stimuli
and hyperpathia [16]. Therefore, the management of









Postoperative 2 h (%) 4 (22.2) 0 (0) 0.046
Postoperative 8 h (%) 9 (50) 3 (15.8) 0.038
Postoperative 24 h (%) 10 (55.6) 4 (21.1) 0.045
Postoperative 48 h (%) 9 (50) 3 (15.8) 0.038
Incidence of PONV (n)
Postoperative 2 h (%) 6 (33.3) 0 (0) 0.008
Postoperative 8 h (%) 8 (44.4) 2 (10.5) 0.029
Postoperative 24 h (%) 6 (33.3) 0 (0) 0.008
Postoperative 48 h (%) 2 (11.1) 0 (0) 0.230
Data are presented as number (proportion).
PONV, postoperative nausea and vomiting.undergoing surgeries resulting in severe postoperative
pain, including major cancer or orthopedic surgery, is
crucial for the long-term postoperative outcome. Unlike
previous reports, this study demonstrates that dex-
medetomidine is effective for an extended period after
surgery, and therefore may improve the postoperative
outcome.
Several studies have demonstrated that dexmedeto-
midine had superior efficacy compared to fentanyl and
remifentanil in pain management during a PACU stay
[12,13,17]. In these studies, the efficacy of dexmedetomi-
dine in alleviating postoperative pain was focused on the
immediate postoperative period; for example, the PACU
stay. This may be related to the pharmacokinetics of
dexmedetomidine; its elimination half-life is 2–3 hours,
with a context-sensitive half-time ranging from 4 to
250 minutes following a 10-minute and an 8-hour infu-
sion, respectively [14]. Although dexmedetomidine has
longer action duration than remifentanil, previous inves-
tigators may have thought that this would not influence
the postoperative period beyond PACU recovery. In con-
trast, the present study suggests that dexmedetomidine
had an effect on pain alleviation until 48 hours after sur-
gery. We attribute this result to the nociceptive cascade.
Nociceptors which are located in laminae II-III of the
dorsal horn and have a wide dynamic range [18] dis-
charge in proportion to the intensity of stimulation, and
high-threshold nociceptors respond only when the
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are sensitized, the threshold for activation is decreased,
discharge rate with activation is increased, and rate of
basal (spontaneous) discharge is increased, resulting in
easier response of nociceptors to incoming stimuli [19].
In addition, postoperative pain itself evokes a higher
stress hormone concentration, which in turn produces
more intense pain [20]. Dexmedetomidine, with its lon-
ger action duration compared to remifentanil, may have
reduced the “no pain control period” interval and the
time from discontinuation of the adjuvant in propofol-
based TIVA to PCA initiation, thereby increasing the
stimulus threshold and resulting in a reduced VAS score
and PCA requirement.
The present findings were not influenced simply by
the longer duration of dexmedetomidine compared to
remifentanil. In a previous report, systemic medetomi-
dine alone at subanesthetic did not significantly influ-
ence the intensity and thresholds of experimental pain
whereas the affective-motivational component of pain
was attenuated [21]. The superior efficacy of pain con-
trol beyond the known duration of dexmedetomidine
(i.e., until 48 hours after surgery) in combination with
similar recovery time in PACU suggest that the alle-
viated postoperative pain over a longer period during
recovery might have been influenced by affective-
emotional effect of dexmedetomidine rather than the
analgesic effect of dexmedetomidine on mechanical
stimuli after surgery.
Another reason for the superior postoperative pain
control efficacy of dexmedetomidine compared to remi-
fentanil may be related to opioid-induced hyperalgesia
(OIH). OIH is characterized by a paradoxical increase in
pain intensity or sensitivity in patients receiving opioids
at high doses or for an extended duration [22,23]. Nu-
merous studies have suggested that intraoperative remi-
fentanil may paradoxically enhance postoperative pain
and hence the opioid analgesic requirement, and this
may occur after 60–90 minutes of infusion [24-26]. A
recent study demonstrated that intraoperative high-dose
remifentanil decreased the mechanical hyperalgesia
threshold, enhanced the pain intensity, reduced the time
to the first postoperative analgesic requirement, and in-
creased patient morphine consumption, indicating OIH,
which was alleviated efficiently using a dexmedetomidine
infusion [4]. In the present study, remifentanil was
infused over 170 minutes at 0.1 ± 0.03 μg/kg/min, which
is sufficient to induce OIH. A higher VAS score and
greater PCA requirement imply OIH, although we did
not apply any other method to confirm its occurrence.
PONV is one of the most undesirable clinical anes-
thesia outcomes [27]. Various factors may induce PONV.
Perioperative opioid use is a major factor in PONV. In
addition, pain itself is an important risk factor for PONV[28,29]. In the present study, dexmedetomidine reduced
PONV for 48 hours after surgery, in agreement with a
previous study [4]. The greater PCA required may have
contributed to the increased PONV incidence in the
remifentanil group. More intense pain may have induced
PONV and thus made patients require more rescue anal-
gesics, mostly opioid, which in turn aggravated PONV.
Therefore, using dexmedetomidine as an adjuvant in
propofol-based TIVA may reduce the incidence of
PONV by alleviating the pain intensity because of a
reduced requirement for postoperative rescue opioids.
Conclusions
In conclusion, dexmedetomidine as an adjuvant in
propofol-based TIVA displayed superior efficacy to remi-
fentanil in alleviating pain and managing postoperative
pain for 48 hours following PLIF surgery. It also reduced
the requirement for rescue analgesics and PONV. There-
fore, dexmedetomidine may be used as an adjuvant in
propofol-based TIVA instead of remifentanil for more
efficient pain and PONV management.
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